Effectiveness of mRNA-1273 Variant-Containing Vaccine Formulation Against Severe Outcomes in Adults Aged 50-64 Years Without Risk Factors for Severe COVID-19

NCT07279766 · clinicaltrials.gov ↗

PHASE4

Phase

ACTIVE_NOT_RECRUITING

Status

285000

Enrollment

OTHER

Sponsor class

Conditions

COVID-19

Interventions

BIOLOGICAL: mRNA-1273 (Moderna COVID-19 vaccine)

Sponsor

Tor Biering-Sørensen

Collaborators

[object Object]